-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

627.O1.6 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL

Symposia: Aggressive Lymphomas: Pharmacologic Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Combination therapy, Non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, Assays, Drug development, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Biological therapies, Treatment Considerations, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Technology and Procedures, Human, Study Population, Measurable Residual Disease , Imaging, Molecular testing
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Ballroom 20AB (San Diego Convention Center)
Moderators:
Eliza A. Hawkes, MD, Austin Health and Matthew Matasar, MD, MS, Rutgers
Disclosures:
Hawkes: AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding, Speakers Bureau; Merck KGaA: Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck Sharpe and Dohme: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Membership on an entity's Board of Directors or advisory committees; Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Speakers Bureau. Matasar: Bayer: Consultancy, Honoraria, Research Funding; Merck: Current equity holder in publicly-traded company; Allogene: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; GM Biosciences: Consultancy, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Johnson & Johnson: Consultancy, Honoraria, Research Funding; Immunovaccine Technologies: Research Funding; ADC Therapeutics: Honoraria; AstraZeneca: Honoraria; BMS/Celgene: Honoraria; Kite: Honoraria; Epizyme: Honoraria; IMV Therapeutics: Honoraria; Pfizer: Honoraria; Takeda: Honoraria; Regeneron Pharmaceuticals, Inc.: Honoraria.

Presentations in this session focus on novel therapies combined with standard immunochemotherapy such as RCHOP or PolaR-CHP in newly diagnosed Diffuse Large B cell Lymphoma
12:00 PM

Catherine S. Diefenbach1, Andrew D. Zelenetz2*, Charles Herbaux, MD, PhD3*, Monica Tani4*, Roch Houot, MD, PhD5*, Mariana Bastos-Oreiro6*, Hervé Tilly7, Thomas Gastinne, MD8*, Catherine Thieblemont, MD9, Wilfred Leung10*, Katerina Hatzi10*, Murali Kesavan11*, Simona Barlera12*, Michelle Boyer10* and Franck Morschhauser, MD, PhD13

1Perlmutter Cancer Center, NYU Langone Health, New York, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Centre Hospitalier Universitaire de Montpellier, Montpellier, France
4Ospedale Santa Maria delle Croci, Ravenna, Italy
5Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou, Rennes, France
6Hematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
7Department of Hematology, Centre Henri Becquerel, Rouen, France
8Centre Hospitalier Universitaire de Nantes, Nantes, France
9Hospital Saint-Louis, Paris, France
10Genentech, Inc., South San Francisco, CA
11F. Hoffmann-La Roche Ltd, London, United Kingdom
12Parexel International, Milan, Italy
13Centre Hospitalier Régional Universitaire de Lille, Lille, France

12:15 PM

Muhit Ozcan, MD1, Eva Gonzalez Barca2*, Tae Min Kim, MD, PhD3*, Ewa Paszkiewicz-Kozik4*, Jan M. Zaucha5*, Stefan Hohaus, MD6*, Marco Ladetto, MD7, Caterina Patti8*, Sebastian Giebel, MD, PhD9*, Tadeusz Robak10*, Ömür Gökmen Sevindik11*, Yulia Volchek12*, Benedetta Puccini, MD13*, Guillermo Rodríguez Garcia14*, Raul Cordoba, MD, PhD15, Okan Seyran16*, Siruo Wang17*, L. Puja Patel17*, Rushdia Yusuf17 and David Lavie18*

1Hematology Department, Ankara University School of Medicine, Cankaya-Ankara, Turkey
2Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
3Seoul National University Hospital, Seoul, Korea, Republic of (South)
4Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
5Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
6Unit of Extramedullary Lymphoproliferative Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
7Department of Translational Medicine, Università del Piemonte Orientale ed SCDU Ematologia AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Piedmont, Italy
8Onco-Hematology Unit, Azienda Ospedaliera Riunita Villa Sofia-Vincenzo Cervello, Palermo, Italy
9Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
10Department of Hematology, Medical University of Lodz, Lodz, Poland
11Department of Hematology, Medipol University Faculty of Medicine, Istanbul, Turkey
12Sheba Medical Center, Ramat Gan, Israel
13Unit of Hematology, Careggi University-Hospital, Florence, Italy
14Hospital Universitario Virgen del Rocío, Seville, Spain
15Health Research Institute, Fundación Jimenez Diaz University Hospital, Madrid, Spain
16Trakya University Balkan Hospital, Istanbul, Turkey
17Merck & Co., Inc., Rahway, NJ
18Hadassah Medical Center, Jerusalem, Israel

12:30 PM

Arnaud Amzallag, PhD1*, Tara Basavanhally, MSc2*, Jason R. Westin, MD3, Marc Hoffmann, MD4, Theodoros P. Vassilakopoulos, MD, PhD5*, Javier Munoz, MD6*, Grzegorz S. Nowakowski, MD7, Floriane Boucaud, PhD2*, Matt Stokes, PhD8*, Akshay Sudhindra, MD2, Anita K. Gandhi, PhD9 and Mark Kaplan, PhD8*

1Bristol Myers Squibb, Cambridge, MA
2Bristol Myers Squibb, Princeton, NJ
3MD Anderson Cancer Center, Houston, TX
4University of Kansas Medical Center, Kansas City, KS
5National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
6Mayo Clinic, Phoenix, AZ
7Mayo Clinic, Rochester, MN
8Bristol Myers Squibb, Summit, NJ
9Hematology, Translational Medicine, Bristol Myers Squibb, Summit, NJ

12:45 PM

Yucai Wang, MD, PhD1, Han W. Tun, MD2, Betsy R. LaPlant, MS1*, Rebecca L. King, MD1*, Ivana N. Micallef1*, Madiha Iqbal, MD2, Allison C. Rosenthal, DO3, Stephen M. Ansell, MD, PhD1, Jose C. Villasboas Bisneto, MD1, Arushi Khurana, MBBS1, Gita Thanarajasingam, MD1, Thomas M. Habermann, MD1, Javier L. Munoz, MD, MS, MBA4, Paul J. Hampel, MD1, Patrick B. Johnston, MD, PhD1*, Thomas E. Witzig, MD1 and Grzegorz S. Nowakowski, MD1

1Mayo Clinic, Rochester, MN
2Mayo Clinic, Jacksonville, FL
3Division of Hematology/Oncology Mayo Clinic, Phoenix, AZ
4Mayo Clinic, Phoenix, AZ

1:00 PM

Lorenzo Falchi, MD1, Fritz Offner, MD, PhD2, Sven de Vos, MD, PhD3*, Joshua Brody, MD4*, Raul Cordoba, MD, PhD5, Kim Linton6*, Sylvia Snauwaert, MD, PhD7*, Michael Roost Clausen, MD, PhD8*, Toshihiko Oki, MD, PhD9*, Andrew J. Steele, PhD10*, Yi Hao, DrPH10*, Kimberly G. Archer10*, Ali Rana, MD, PhD10* and David Belada, MD, PhD11

1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Universitair Ziekenhuis Ghent, Ghent, Belgium
3Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
4Icahn School of Medicine at Mount Sinai, New York, NY
5Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
6The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
7Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium
8Vejle Hospital, Vejle, Denmark
9AbbVie, North Chicago, IL
10Genmab, Plainsboro, NJ
114th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

1:15 PM

Adrian Minson, MBBS1,2, Emma Verner, MBBS3*, Pratyush Giri, MBBS4*, Jason Butler, MBBS5*, Wojt Janowski, MD6*, Chan Y. Cheah, MBBS, DMSc7*, Sumita Ratnasingam, MBBS8, Shu Min Wong, MBBS9*, Matthew Ku, MBBS, PhD10*, Mark S. Hertzberg, MBBS11, Kirsten Herbert, MBBS, PhD12*, Nada Hamad, MBBS, MSc, BSc13, Costas K. Yannakou, MBBS, PhD14*, Fiona Swain15*, Paul Neeson, PhD16*, Thiago M. Steiner, PhD16*, Javad Saghebi, MBBS16*, Piers Blombery, MBBS1,17, Molly Robertson, RN16*, Lei Shong Lau, PhD16*, Jing Xie, PhD16*, Rory Bennett, MBChB2*, John F. Seymour, MBBS, PhD1,18 and Michael J. Dickinson, MBBS, DMedSci1,2

1Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
2Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC, Australia
3Concord Repatriation General Hospital, Concord, NSW, Australia
4Royal Adelaide Hospital, Adelaide, Australia
5Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
6Calvary Mater Newcastle, Newcastle, NSW, Australia
7Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia
8University Hospital, Geelong, Australia
9Alfred Hospital, Melbourne, Australia
10St Vincent’s Hospital, Melbourne, VIC, Australia
11Prince of Wales Hospital, Sydney, NSW, Australia
12Cabrini Health, Melbourne, VIC, Australia
13St Vincent's Hospital, Sydney, NSW, Australia
14Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, VIC, Australia
15Department of Haematology, Princess Alexandra Hospital, Woolloongabba, Australia
16Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
17Peter Maccallum Cancer Centre, East Melbourne, VIC, Australia
18Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

*signifies non-member of ASH